{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:00:04Z","timestamp":1787169604014,"version":"build-2736575974"},"reference-count":19,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T00:00:00Z","timestamp":1618099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001962","name":"World Anti-Doping Agency","doi-asserted-by":"publisher","award":["12D14MP"],"award-info":[{"award-number":["12D14MP"]}],"id":[{"id":"10.13039\/501100001962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Salmeterol and fluticasone are included in the Prohibited List annually issued by the World Anti\u2010Doping Agency. While for other permitted beta\u20102 agonists a threshold has been established, above which any finding constitutes an Adverse Analytical Finding, this is not the case with salmeterol. The salmeterol metabolite,\n                    <jats:italic>\u03b1<\/jats:italic>\n                    \u2010hydroxysalmeterol, has been described as a potentially more suitable biomarker for the misuse of inhaled salmeterol. In this study, a new and rapid UHPLC\u2013QTOF\u2013MS method was developed and validated for the simultaneous quantification of salmeterol,\n                    <jats:italic>\u03b1<\/jats:italic>\n                    \u2010hydroxysalmeterol and fluticasone in human urine and plasma, which can be used for doping control. The analytes of interest were extracted by means of solid phase extraction and were separated on a Zorbax Eclipse Plus C\n                    <jats:sub>18<\/jats:sub>\n                    column. Detection was performed in a quadrupole time\u2010of\u2010flight mass spectrometer equipped with an electrospray ionization source, in positive mode for the detection of salmeterol and its metabolite and in negative mode for the detection of fluticasone. Method was validated over a linear range from 0.10\u00a0to 2.00\u2009ng\/ml for salmeterol and fluticasone, and from 1.00\u2009to 20.0\u00a0ng\/ml for\n                    <jats:italic>\u03b1<\/jats:italic>\n                    \u2010hydroxysalmeterol, in urine, whereas in plasma, the linear range was from 0.025\u2009to 0.500\u2009ng\/ml for salmeterol and fluticasone, respectively.\n                  <\/jats:p>","DOI":"10.1002\/bmc.5114","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T07:25:54Z","timestamp":1615793154000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Determination of salmeterol,\n                    <i>\u03b1<\/i>\n                    \u2010hydroxysalmeterol and fluticasone propionate in human urine and plasma for doping control using UHPLC\u2013QTOF\u2013MS"],"prefix":"10.1002","volume":"35","author":[{"given":"Panagiotis","family":"Sakellariou","sequence":"first","affiliation":[{"name":"Doping Control Laboratory of Athens, Institute of Biosciences and Applications National Centre for Scientific Resarch \u201cDemokritos\u201d  Maroussi Greece"},{"name":"Faculty of Biology, School of Science National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6379-1220","authenticated-orcid":false,"given":"Michael","family":"Petrou","sequence":"additional","affiliation":[{"name":"Cyprus Anti\u2010Doping Authority  Nicosia Cyprus"},{"name":"University of Nicosia  Nicosia Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Lyris","sequence":"additional","affiliation":[{"name":"Doping Control Laboratory of Athens, Institute of Biosciences and Applications National Centre for Scientific Resarch \u201cDemokritos\u201d  Maroussi Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tsivou","sequence":"additional","affiliation":[{"name":"Dopingkontroll\u2010Labor Chemical Analytics Seibersdorf Labor GmbH  Seibersdorf Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argyro","family":"Fragkaki","sequence":"additional","affiliation":[{"name":"Doping Control Laboratory of Athens, Institute of Biosciences and Applications National Centre for Scientific Resarch \u201cDemokritos\u201d  Maroussi Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polyxeni","family":"Kiousi","sequence":"additional","affiliation":[{"name":"Doping Control Laboratory of Athens, Institute of Biosciences and Applications National Centre for Scientific Resarch \u201cDemokritos\u201d  Maroussi Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiannis S.","family":"Angelis","sequence":"additional","affiliation":[{"name":"Doping Control Laboratory of Athens, Institute of Biosciences and Applications National Centre for Scientific Resarch \u201cDemokritos\u201d  Maroussi Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6391-3224","authenticated-orcid":false,"given":"Constantinos","family":"Pistos","sequence":"additional","affiliation":[{"name":"Department of Chemistry West Chester University of Pennsylvania  West Chester PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,4,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2011.11.018"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(98)00374-0"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2007.06.010"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2008.10.034"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241010-00003"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318229c5f4"},{"key":"e_1_2_7_9_1","first-page":"2","article-title":"Urine concentrations of inhaled salmeterol and its metabolite \u03b1\u2010hydroxysalmeterol in asthmatic and non\u2010asthmatic subjects","volume":"2","author":"Hostrup M.","year":"2012","journal-title":"Journal of Sports Medicine & Doping Studies"},{"key":"e_1_2_7_10_1","first-page":"1","article-title":"The salmeterol anomaly and the need for a urine threshold","author":"Jacobson G. A.","year":"2020","journal-title":"Drug Testing and Analysis"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2131"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2009.10.009"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac020361s"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1708"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2015.08.009"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2004.03.005"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2012.11.031"},{"key":"e_1_2_7_18_1","unstructured":"WADA. World Anti\u2010Doping Agency. (2019).WADA Technical Document on Decision Limits for the Confirmatory Quantification of Threshold Substances (TD2019DL).https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/td2019dl_v2_finalb.pdf Accessed date: 30 April 2020."},{"key":"e_1_2_7_19_1","unstructured":"WADA. World Anti\u2010Doping Agency. (2020).The 2020 Prohibited List.https:\/\/www.wada-ama.org\/sites\/default\/files\/wada_2020_english_prohibited_list_0.pdf Accessed date: 30 April 2020."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bku143"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.5114","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bmc.5114","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.5114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T22:48:24Z","timestamp":1760050104000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.5114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,11]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1002\/bmc.5114"],"URL":"https:\/\/doi.org\/10.1002\/bmc.5114","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,11]]},"assertion":[{"value":"2020-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e5114"}}